Romosozumab
Based on 1 publication(s) in Google Scholar
Romosozumab is a humanized monoclonal anti-sclerostin antibody, it promotes bone formation and inhibits bone resorption by inhibiting sclerostin. Romosozumab can be used for the research of osteoporosis.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 99.11%
- CAS. Nr.: 909395-70-6
- Molecular Weight:146.32 kDa
-
Speicherung:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
Biologische Aktivität
Beschreibung
IC50 & Target
SOST/Sclerostin
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male cynomolgus monkeys[1]
-
Dosage:30 mg/kg
-
Administration:Subcutaneous injection; 30 mg/kg twice a week for 10 weeks
-
Result:Increased bone formation and plate-like trabecular morphology, and improved mechanical performance.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Anwendung
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized SOST Protein, Human can bind Romosozumab. The EC50 for this effect is 12.46 ng/mL.
Product Details
-
CAS. Nr. 909395-70-6
-
Accession Q9BQB4
-
Synonyms AMG-785; CDP-7851
-
Molecular Weight 146.32 kDa
-
Species Reactivity
Human
-
Conjugated
Unconjugated
-
Isotype
Human IgG2 kappa
-
Recommend Isotype Controls
-
Format
-
Human IgG2 kappa
-
Product Properties
-
Appearance
Liquid
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Reinheit
99.11%
-
Reconstitution
The product can be reconstituted/diluted with sterile PBS or saline.
-
Storage & Stability
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Versand
Shipping with dry ice.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Phytomedicine
Schisandrol B inhibits osteoclastogenesis and mitigates estrogen deficiency-induced bone loss by targeting TRAF6-NOX1 pathway. [Abstract]2026 Jan:150:157669. PMID: 41435606
Romosozumab purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2026 Jan:150:157669. [Abstract]
Representative images of mature OCs (nuclei≥3) treated with SolB, Denosumab, and Romosozumab (5 μM) and quantitation of mature OCs.
Reinheit & Dokumentation
Verweise
[1]. Paik J, Scott LJ. Romosozumab: A Review in Postmenopausal Osteoporosis. Drugs Aging. 2020 Nov;37(11):845-855. [Content Brief]
[2]. Ominsky MS, et al. Romosozumab Improves Bone Mass and Strength While Maintaining Bone Quality in Ovariectomized Cynomolgus Monkeys. J Bone Miner Res. 2017 Apr;32(4):788-801. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)